Trial Profile
Efficacy of NGM-282 patients with biopsy-proven non-alcoholic steatohepatitis independent of type 2 diabetes status and statin usage: A phase II study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2018
Price :
$35
*
At a glance
- Drugs Aldafermin (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 20 Jul 2018 New trial record
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association